NCT03194217View on ClinicalTrials.gov

BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

PHASE2CompletedINTERVENTIONAL

Enrollment

244

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

May 28, 2019

Study Completion Date

May 28, 2019

Conditions

Excessive Daytime SleepinessParkinson Disease

Interventions

DRUG

BEN-2001

Bavisant dihydrochloride monohydrate for oral use

DRUG

Placebo

Placebo

Trial Locations (1)

33018

MaxBlue Institute, Miami

Sponsors

Lead Sponsor

BenevolentAI Bio

All Listed Sponsors

lead

BenevolentAI Bio

INDUSTRY

NCT03194217 - BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness | Biotech Hunter | Biotech Hunter